[CAS NO. 168555-66-6]  Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [168555-66-6]

Catalog
SLK-S7204
Brand
Selleck
CAS
168555-66-6

DESCRIPTION [168555-66-6]

Overview

MDLMFCD00943911
Molecular Weight440.29
Molecular FormulaC18H19O8P.2Na
SMILESO(P(=O)(O)O)C1=C(OC)C=CC(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)=C1.[Na]

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Description

Fosbretabulin (Combretastatin A4 Phosphate, CA4P, CA 4DP) Disodium is the water-soluble prodrug of Combretastatin A4 (CA4), which is a -targeting agent that binds β-tubulin with of 0.4 μM in a cell-free assay. Fosbretabulin Disodium inhibits the polymerization of tubulin with of 2.4 μM, and also disrupts tumor vasculature. Fosbretabulin disodium induces mitotic arrest and in endothelial cells. Phase 3.

Features

A microtubule associated inhibitor with higher affinity to β-tubulin vs. Colchicine. Best for advanced solid tumors, anaplastic thyroid cancer, & choroidal neovascularization.

Targets

Tubulin [1]
(Cell-free assay)
2.4 μM

In vitro

Fosbretabulin disodium (Combretastatin A-4 phosphate disodium, CA4P disodium) is the water-soluble prodrug of combretastatin A4 (CA4), which is originally isolated from African tree . CA4 is a tubulin-binding agent that binds at or near the colchicine binding site of β-tubulin (Kd = 0.40 μM), inhibits tubulin assembly with IC50 of 2.4 μM. CA4 is cytotoxic towards proliferating but not quiescent endothelial cells, has potent and selective toxicity towards tumor vasculature. CA4P (1 mM, 30 minutes) disrupts the endothelial microtubule cytoskeleton and mediates changes in endothelial cell morphology. CA4P stimulates actin stress fiber formation and membrane blebbing and increases monolayer permeability via Rho/Rho-kinase. CA4P increases endothelial cell permeability, while inhibiting endothelial cell migration and capillary tube formation predominantly through disruption of VE-cadherin/β-catenin/Akt signaling pathway, thereby leading to rapid vascular collapse and tumor necrosis.

In vivo

CA4P causes rapid, extensive and irreversible vascular shutdown in experimental tumor models following the administration of a single dose at 10% of the maximum tolerated dose (MTD). CA4P causes a 93% reduction in vascular volume 6 h following drug administration. CA4P(100 mg/kg, 6 h following administration) reduces tumor blood by approximately 100-fold, compared with approximately 7-fold in the spleen.


Synonyms

Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, 1-(dihydrogen phosphate), sodium salt (1:2)
Phenol, 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, disodium salt, (Z)-
Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, disodium salt
Combretastatin A4 disodium phosphate
Fosbretabulin disodium
Fosbretabulin disodium salt
CA 4DP
CA 4P
SML1131